Nerve health support during bladder cancer treatment
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study looks at a new treatment for advanced bladder cancer (urothelial carcinoma) using two drugs, enfortumab vedotin and pembrolizumab, which help the immune system fight cancer. The study also tests a supportive therapy called Neuridase to help prevent or reduce nerve damage (peripheral neuropathy) that can be a side effect of the cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or metastatic bladder cancer (urothelial carcinoma) confirmed by biopsy.
- Your doctor has decided that treatment with enfortumab vedotin and pembrolizumab is right for you.
- You do not have severe nerve damage (peripheral neuropathy) before starting the study.
- You are not pregnant or breastfeeding, and you can give informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) given before surgery to shrink or eliminate bladder or upper tract cancer. The goal is to see if this approach reduces the chance of cancer coming back and improves outcomes.
This study looks at nerve problems (peripheral neuropathy) in people with muscle-invasive bladder cancer who receive a combination of two drugs, enfortumab vedotin and pembrolizumab, before or after surgery. The goal is to understand how these treatments affect nerves and to help manage side effects.
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
This trial looks at how a new treatment for advanced bladder cancer, called enfortumab vedotin, might affect your nerves. It aims to understand any nerve-related side effects so doctors can better manage them.
This study looks at how enfortumab vedotin, a cancer drug, affects the nerves. It aims to understand and track neuropathy (nerve damage) in people with urothelial carcinoma, so doctors can better manage side effects.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Hear when a new Peripheral Nerve Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.